Nanjing Well Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceutical excipients and synthetic lubricating base oils. The Company's products mainly include mechanical synthetic lubricating base oils, non-mechanical synthetic lubricating base oils, injectable pharmaceutical excipients, and non-injectable pharmaceutical excipients. The Company distributes its products within the domestic market and to overseas markets.

Employees

718

Sector

Oil & Gas Refining and Marketing

Calendar

10-29 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	CN¥26.68	+1.56%	3,096,400
22/10/26	CN¥26.27	-6.18%	4,758,070
21/10/26	CN¥28.00	+4.28%	5,795,560
20/10/26	CN¥26.85	+0.90%	1,367,460
19/10/26	CN¥26.61	-0.82%	2,592,256

End-of-day quote Shanghai S.E.

More quotes

End-of-day quote Shanghai S.E. 23/10/2026			5-day change	1st Jan Change
26.68 ^CNY	+1.56%		-0.56%	+2.54%

10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	CI
10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	CI

Market Cap	3.61B 542M 484M 447M 405M 758M 51.43B 770M 5.38B 2.13B 26.94B 2.03B 1.99B 84.95B	P/E 2024	22.7x	P/E 2025	23.4x
Enterprise Value	3.76B 564M 504M 466M 422M 789M 53.57B 802M 5.6B 2.22B 28.07B 2.12B 2.07B 88.49B	EV / Sales 2024	2.75x	EV / Sales 2025	2.75x
Free-Float	38.51%	Yield 2024	1.63%	Yield 2025	2.31%

10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	CI
10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	CI
08-21	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-16	Nanjing Well Pharmaceutical Group Co.,Ltd. signed a property rights transaction contract to acquire 50.98% stake in Lianyungang Wantai Pharmaceutical Excipients Technology Co., Ltd. from Tianjin Boguang Medical Biotechnology Development Co., Ltd. for CNY 19.4 million.	CI
06-10	Nanjing Well Pharmaceutical Completes Updating Business Scope Registration	MT
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. announces Annual dividend, payable on June 05, 2026	CI
29/10/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
19/08/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/04/25	Nanjing Well Pharmaceutical Group Co.,Ltd. announces Annual dividend, payable on June 13, 2025	CI
21/04/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
21/04/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	+1.56%
1 week	-0.56%
Current month	-2.84%
1 month	-3.16%
3 months	+13.53%
6 months	+3.73%
Current year	+2.54%

Nanjing Well Pharmaceutical Group Co.,Ltd. Stock

Stocks

603351

CNE100003JD4

Oil & Gas Refining and Marketing

Valuation: Nanjing Well Pharmaceutical Group Co.,Ltd.

Chart: Nanjing Well Pharmaceutical Group Co.,Ltd.

Latest news: Nanjing Well Pharmaceutical Group Co.,Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Nanjing Well Pharmaceutical Group Co.,Ltd.

Latest insider transactions

Other Oil & Gas Refining and Marketing

Financials

Company Profile

Quotes

1 week	25.03	29.54
1 month	25.03	29.54
Current year	21.9	29.54
1 year	21.9	30.8
3 years	17.65	33.34
5 years	17.65	42.62
10 years	17.08	42.62

Manager	Title	Age	Since
Ren Rong Wu CEO	Chief Executive Officer	63	25/03/2017
Qun Song Tang DFI	Director of Finance/CFO	59	25/03/2017
Zheng Song Gao CTO	Chief Tech/Sci/R&D Officer	61	25/03/2017

Director	Title	Age	Since
Ren Rong Wu CHM	Chairman	63	25/03/2017
Zheng Song Gao BRD	Director/Board Member	61	25/03/2017
Xin Guo Chen BRD	Director/Board Member	58	25/03/2017

	2024	2025
Net sales	1.3B 194M 174M 160M 145M 272M 18.46B 276M 1.93B 764M 9.67B 730M 714M 30.48B	1.34B 200M 179M 165M 150M 280M 19B 285M 1.99B 787M 9.95B 751M 735M 31.38B
Net income	146M 21.95M 19.6M 18.11M 16.41M 30.7M 2.08B 31.21M 218M 86.28M 1.09B 82.38M 80.63M 3.44B	151M 22.63M 20.21M 18.67M 16.92M 31.66M 2.15B 32.18M 225M 88.96M 1.13B 84.94M 83.13M 3.55B
Net Debt	234M 35.09M 31.33M 28.95M 26.23M 49.08M 3.33B 49.89M 348M 138M 1.75B 132M 129M 5.5B	151M 22.61M 20.19M 18.65M 16.9M 31.62M 2.15B 32.15M 224M 88.86M 1.12B 84.85M 83.05M 3.55B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.	+1.56%	-0.56%	-2.16%	+5.96%	542M
EXXONMOBIL HOLDINGS CORPORATION	+2.79%	+2.36%	+57.97%	+67.39%	753B
RELIANCE INDUSTRIES LTD	+0.46%	-1.75%	-17.84%	+5.16%	170B
MARATHON PETROLEUM CORPORATION	-0.45%	-4.36%	+133.32%	+205.94%	128B
BP PLC	+4.35%	+3.97%	+46.13%	+19.97%	132B
VALERO ENERGY CORPORATION	-1.64%	-5.72%	+142.18%	+220.72%	121B
PHILLIPS 66	-0.51%	-3.41%	+108.51%	+150.49%	113B
SUNCOR ENERGY INC.	+2.57%	+0.84%	+100.61%	+142.33%	92.97B
CHINA PETROLEUM & CHEMICAL CORPORATION	+0.45%	-0.89%	+6.19%	+9.31%	91.62B
IMPERIAL OIL LIMITED	+2.13%	-0.40%	+50.23%	+134.76%	65.25B
Average	+1.17%	-0.84%	+62.51%	+96.20%	166.75B
Weighted average by Cap.	+1.72%	+0.23%	+63.85%	+88.31%